C.R. Bard Acquires Lutonix for $325,000,000

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    7351 Kirkwood Lane North Maple Grove, MN 55369
  • Company Description
    The Vision of Lutonix is to improve the quality of life for patients with vascular disease through innovative solutions.

    The Mission of Lutonix is to rapidly develop and commercialize the safest and most efficacious drug coated balloon catheters for treatment of vascular disease.

  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    C. R. Bard, Inc. (NYSE: BCR) today announced that it has acquired Lutonix, Inc. for a purchase price of approximately $225 million paid at closing, with an additional $100 million to be paid upon PMA approval of Lutonix’s drug-coated percutaneous transluminal angioplasty (PTA) balloon. The transaction is structured as a merger.

Trending on Xconomy